
Privacy notice | Accessibility statement | Terms and conditions | Login | Contact |
UK data driving real-world evidence
Bibliography
Research using CPRD data has informed drug safety guidance and clinical practice and resulted in over 2,700 peer-reviewed publications. The CPRD bibliography is updated on a monthly basis (last updated 5 February 2021) and papers are listed below and in the PDF below.
If you have published papers using CPRD data which are not included in this list, please contact us at enquiries@cprd.com so that we can update the bibliography.
Download:
(PDF, 3MB, 220 pages)This work uses data provided by patients and collected by the NHS as part of their care and support. CPRD encourages researchers to use this citation in all publications using CPRD data. Find out more about acknowledging the use of patient data at the Understanding Patient Data website.
“Oral corticosteroids and fracture risk: relationship to daily and cumulative doses”, Rheumatology (Oxford), vol. 39, pp. 1383-9, 2000.
, “The use of a large pharmacoepidemiological database to study exposure to oral corticosteroids and risk of fractures: validation of study population and results”, Pharmacoepidemiol Drug Saf, vol. 9, pp. 359-66, 2000.
, “Use of nonsteroidal anti-inflammatory drugs and risk of fractures”, Bone, vol. 27, pp. 563-8, 2000.
, “Use of oral corticosteroids and risk of fractures”, J Bone Miner Res, vol. 15, pp. 993-1000, 2000.
, “Use of oral corticosteroids in the United Kingdom”, Qjm, vol. 93, pp. 105-11, 2000.
, “Epidemiology of fractures in England and Wales”, Bone, vol. 29, pp. 517-22, 2001.
, “Public health impact of adverse bone effects of oral corticosteroids”, Br J Clin Pharmacol, vol. 51, pp. 601-7, 2001.
, “Use of inhaled corticosteroids and risk of fractures”, J Bone Miner Res, vol. 16, pp. 581-8, 2001.
, “Does a fracture at one site predict later fractures at other sites? A British cohort study”, Osteoporos Int, vol. 13, pp. 624-9, 2002.
, “Incidence and natural history of Paget's disease of bone in England and Wales”, J Bone Miner Res, vol. 17, pp. 465-71, 2002.
, “Utility of medical and drug history in fracture risk prediction among men and women”, Bone, vol. 31, pp. 508-14, 2002.
, “Children and the risk of fractures caused by oral corticosteroids”, J Bone Miner Res, vol. 18, pp. 913-8, 2003.
, “Neutropenia and agranulocytosis in England and Wales: incidence and risk factors”, Am J Hematol, vol. 72, pp. 248-54, 2003.
, “Use of alpha-blockers and the risk of hip/femur fractures”, J Intern Med, vol. 254, pp. 548-54, 2003.
, “The use of inhaled corticosteroids in the United Kingdom and the Netherlands”, Respir Med, vol. 97, pp. 578-85, 2003.
, “5-aminosalicylic acids and the risk of renal disease: a large British epidemiologic study”, Gastroenterology, vol. 126, pp. 1733-9, 2004.
, “Are inhaled corticosteroids associated with an increased risk of fracture in children?”, Osteoporos Int, vol. 15, pp. 785-91, 2004.
, “Epidemiology of childhood fractures in Britain: a study using the general practice research database”, J Bone Miner Res, vol. 19, pp. 1976-81, 2004.
, “Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular disease in a population based case-control study”, Heart, vol. 90, pp. 859-65, 2004.
, “5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study”, Gut, vol. 54, pp. 1573-8, 2005.
, “Severity of obstructive airway disease and risk of osteoporotic fracture”, Eur Respir J, vol. 25, pp. 879-84, 2005.
, “A simple score for estimating the long-term risk of fracture in patients using oral glucocorticoids”, Qjm, vol. 98, pp. 191-8, 2005.
, “Clinical assessment of the long-term risk of fracture in patients with rheumatoid arthritis”, Arthritis Rheum, vol. 54, pp. 3104-12, 2006.
, “Difference in risks of allergic reaction to sulfonamide drugs based on chemical structure”, Ann Pharmacother, vol. 40, pp. 1040-6, 2006.
, “Risk of aplastic anemia in patients using antiepileptic drugs”, Epilepsia, vol. 47, pp. 1232-6, 2006.
, “Statin treatment and reduced risk of pneumonia in patients with diabetes”, Thorax, vol. 61, pp. 957-61, 2006.
, “Angiotensin-converting enzyme inhibitor use and protection against pneumonia in patients with diabetes”, J Hypertens, vol. 25, pp. 235-9, 2007.
, “Fracture risk with intermittent high-dose oral glucocorticoid therapy”, Arthritis Rheum, vol. 56, pp. 208-14, 2007.
, “Individual fracture risk and the cost-effectiveness of bisphosphonates in patients using oral glucocorticoids”, Rheumatology (Oxford), vol. 46, pp. 460-6, 2007.
, “Lithium use and the risk of fractures”, Bone, vol. 40, pp. 1252-8, 2007.
, “Use of beta-blockers and the risk of hip/femur fracture in the United Kingdom and The Netherlands”, Calcif Tissue Int, vol. 80, pp. 69-75, 2007.
, “Changes in the characteristics of patients prescribed selective cyclooxygenase 2 inhibitors after the 2004 withdrawal of rofecoxib”, Arthritis Rheum, vol. 59, pp. 1105-11, 2008.
, “Does the varied use of NSAIDs explain the differences in the risk of myocardial infarction?”, J Intern Med, vol. 264, pp. 481-92, 2008.
, “Evaluating drug toxicity signals: is a hierarchical classification of evidence useful or a hindrance?”, Pharmacoepidemiol Drug Saf, vol. 17, pp. 475-84, 2008.
, “Individualizing the risks and benefits of postmenopausal hormone therapy”, Menopause, vol. 15, pp. 374-81, 2008.
, “Psychiatric and cardiovascular comorbidities in patients with diabetes mellitus starting antiobesity drugs”, Obesity (Silver Spring), vol. 16, pp. 2331-5, 2008.
, “What is the harm-benefit ratio of Cox-2 inhibitors?”, Int J Epidemiol, vol. 37, pp. 405-13, 2008.
, “A comparison of cost effectiveness using data from randomized trials or actual clinical practice: selective cox-2 inhibitors as an example”, PLoS Med, vol. 6, p. e1000194, 2009.
, “Risk of death and cardiovascular outcomes with thiazolidinediones: a study with the general practice research database and secondary care data”, PLoS One, vol. 6, p. e28157, 2011.
, “The risk of fracture in patients with multiple sclerosis: the UK general practice research database”, J Bone Miner Res, vol. 26, pp. 2271-9, 2011.
, “Causes of death in patients with multiple sclerosis and matched referent subjects: a population-based cohort study”, Eur J Neurol, vol. 19, pp. 1007-14, 2012.
, “Risk of cataract and glaucoma in patients with multiple sclerosis”, Mult Scler, vol. 18, pp. 628-38, 2012.
, “A simple score for estimating the long-term risk of fracture in patients with multiple sclerosis”, Neurology, vol. 79, pp. 922-8, 2012.
, “Use of statins is associated with an increased risk of rheumatoid arthritis”, Ann Rheum Dis, vol. 71, pp. 648-54, 2012.
, “Fracture rate in patients with myasthenia gravis: the general practice research database”, Osteoporos Int, vol. 24, pp. 467-76, 2013.
, “The patterns of anticoagulation control and the risk of stroke, bleeding and mortality in patients with non-valvular atrial fibrillation”, J Thromb Haemost, vol. 11, pp. 107-15, 2013.
, “Patterns of risk of cancer in patients with metal-on-metal hip replacements versus other bearing surface types: a record linkage study between a prospective joint registry and general practice electronic health records in England”, PLoS One, vol. 8, p. e65891, 2013.
, “Risk of fracture with thiazolidinediones: an individual patient data meta-analysis”, Front Endocrinol (Lausanne), vol. 4, p. 11, 2013.
, “Antidepressant prescribing in five European countries: application of common definitions to assess the prevalence, clinical observations, and methodological implications”, Eur J Clin Pharmacol, vol. 70, pp. 849-57, 2014.
, “Mortality in British hip fracture patients, 2000-2010: a population-based retrospective cohort study”, Bone, vol. 66, pp. 171-7, 2014.
,